But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

Asian shares are mixed in thin holiday trading, with most markets in the region and elsewhere closed for Christmas ...

Wall Street closed higher and reached more records Wednesday on a holiday-shortened trading day. Trading was extremely light ...

NEW YORK — Wall Street slightly higher in midday trading Wednesday as markets hovered near record levels on a ...

Novo Nordisk A/S is rated a Buy with improved execution and valuation gap with LLY to drive outperformance through 2026. Read ...

Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm still bullish on LLY stock.

Three inmates, all accused of violent crimes, are back in custody after escaping from an Atlanta-area jail. It’s still unclear exactly how they got out, but police say their recorded jailhouse phone ...

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market ...

The first GLP-1 pill specifically for obesity, also branded as Wegovy, is a 25-mg oral formulation of semaglutide, the active ingredient in the blockbuster injectable version ...

Global pharmaceutical leaders Eli Lilly and Novo Nordisk are intensifying competition in Indias rapidly expanding obesity ...

A shaky economy, wider adoption of weight-loss medication, and changing tastes seem to conspire against some food makers. A strained economy, the growing number of people on weight-loss drugs and ...

Eli Lilly stock was on the outside looking in on Tuesday as shares of Novo Nordisk, its rival in diabetes and weight-loss drugs, soared after the company secured regulatory approval for a weight-loss ...